Clinical Trial Search

Primary: Area Under the Concentration-Time Curve (AUC) of Pembrolizumab - Cohort A — 507; 480; 695 mg*day/L

Primary: Safety and Tolerability: the Number of Subjects Experiencing Treatment Emergent Adverse Events — 1; 0; 1; 1 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events of HM15912 — 3; 1; 2; 4 Participants

Primary: Number of Participants Who Had a Dose Limiting Toxicity (DLT) Following Treatment With Enadenotucirev and Chemoradiotherapy (Capecitabine and Radiation) at 1 of 4…

Primary: To Quantify BCG Recoverable From Bronchial Sample — 0; 0; 0; 0 Volunteers with detectable BCG

Primary: Number of Grades 3, 4, and/or 5 Dose-limiting Toxicities (DLT) Probably and/or Definitely Related to Triplet Combination Therapy — 0; 2; 0; 0 Adverse events

Primary: Characterize the Safety and Tolerability of EXT608 — 2; 2; 0; 0 Participants

Primary: SAD: Number of Subjects Reporting TEAEs and STEAEs — 0; 0; 0; 1 participants

Primary: Frequency of Any New-onset Chronic Medical Conditions (NOCMCs) — 0; 0; 2; 0 Participants

Primary: Total Number of Treatment Emergent Adverse Events (AEs) and Serious AEs (SAEs) — 5; 5; 3; 2 Number of events

Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants

Primary: Primary Safety Endpoint — 7; 8; 10 Participants — p=>0.05

Primary: Percentage of Participants With Shigellosis Following Shigella Challenge — 59.1; 80.0; 15.8; 58.3 percentage of participants

Primary: Safety Profile of SL-172154 — 3; 6; 4; 9 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of PF-07817883 — 2308; 2579; 4266; 3566 nanogram per milliliter (ng/mL)